Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology
Authors
Keywords
-
Journal
Pharmacology Research & Perspectives
Volume 9, Issue 2, Pages -
Publisher
Wiley
Online
2021-03-11
DOI
10.1002/prp2.723
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Critical considerations in the formulation development of parenteral biologic drugs
- (2020) Bilikallahalli K. Muralidhara et al. DRUG DISCOVERY TODAY
- Corneal neovascularization is inhibited with nucleolin-binding aptamer, AS1411
- (2020) Oscar Vivanco-Rojas et al. EXPERIMENTAL EYE RESEARCH
- Advances and limitations of drug delivery systems formulated as eye drops
- (2020) Clotilde Jumelle et al. JOURNAL OF CONTROLLED RELEASE
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
- (2020) Daniel F. Martin et al. OPHTHALMOLOGY
- Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives
- (2020) Hilal Ahmed Parray et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Novel peptide derived from IGF ‐2 displays anti‐angiogenic activity in vitro and inhibits retinal angiogenesis in a model of oxygen‐induced retinopathy
- (2020) Ying Zheng et al. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Novel hybrid lipid nanocapsules loaded with a therapeutic monoclonal antibody – Bevacizumab – and Triamcinolone acetonide for combined therapy in neovascular ocular pathologies
- (2020) María Lina Formica et al. Materials Science & Engineering C-Materials for Biological Applications
- Long-acting intraocular delivery strategies for biological therapy of age-related macular degeneration
- (2019) Shwetha Iyer et al. JOURNAL OF CONTROLLED RELEASE
- Transscleral Delivery of Bevacizumab-Loaded Chitosan Nanoparticles
- (2019) Nagihan Ugˇurlu et al. Journal of Biomedical Nanotechnology
- Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy
- (2019) Jian-Guo Sun et al. International Journal of Nanomedicine
- Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties
- (2019) Astrid Subrizi et al. DRUG DISCOVERY TODAY
- Gene and Induced Pluripotent Stem Cell Therapy for Retinal Diseases
- (2019) Akiko Maeda et al. Annual Review of Genomics and Human Genetics
- Chitosan grafted-poly(ethylene glycol) methacrylate nanoparticles as carrier for controlled release of bevacizumab
- (2019) Corina-Lenuța Savin et al. Materials Science & Engineering C-Materials for Biological Applications
- In vivo effect of bevacizumab-loaded albumin nanoparticles in the treatment of corneal neovascularization
- (2019) Inés Luis de Redín et al. EXPERIMENTAL EYE RESEARCH
- Agents for the prevention and treatment of age-related macular degeneration and macular edema: a literature and patent review
- (2019) Claudiu T. Supuran EXPERT OPINION ON THERAPEUTIC PATENTS
- In vitro characterization of new stabilizing albumin nanoparticles as a potential topical drug delivery system in the treatment of corneal neovascularization (CNV)
- (2019) Juan M. Llabot et al. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
- Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets
- (2019) Xiangke Yin et al. PHARMACOLOGICAL RESEARCH
- Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion
- (2019) Philip Hykin et al. JAMA Ophthalmology
- Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease
- (2019) Yusaku Matsuda et al. Molecular Therapy-Nucleic Acids
- THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors
- (2019) Stephen P H Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- Novel anti-angiogenic PEDF-derived small peptides mitigate choroidal neovascularization
- (2019) Nader Sheibani et al. EXPERIMENTAL EYE RESEARCH
- Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications
- (2019) Jiaxin Liu et al. International Journal of Nanomedicine
- Triamcinolone acetonide-loaded lipid nanocapsules for ophthalmic applications
- (2019) M.L. Formica et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- A Small-Molecule Pan-Id Antagonist Inhibits Pathologic Ocular Neovascularization
- (2019) Paulina M. Wojnarowicz et al. Cell Reports
- In vivo characterization of RC28-E, a fusion protein targeting VEGF and bFGF: Pharmacokinetics and ocular distribution in primates
- (2019) Jing Jiang et al. EXPERIMENTAL EYE RESEARCH
- Preclinical Evaluation of a Cell-Based Gene Therapy Using the Sleeping Beauty Transposon System in Choroidal Neovascularization
- (2019) Maria Hernandez et al. Molecular Therapy-Methods & Clinical Development
- Nanoparticles provide long-term stability of bevacizumab preserving its antiangiogenic activity
- (2018) Flávia Sousa et al. Acta Biomaterialia
- Ocular delivery of proteins and peptides: Challenges and novel formulation approaches
- (2018) Abhirup Mandal et al. ADVANCED DRUG DELIVERY REVIEWS
- Overcoming ocular drug delivery barriers through the use of physical forces
- (2018) Di Huang et al. ADVANCED DRUG DELIVERY REVIEWS
- Fármacos biológicos y biosimilares: aclarando conceptos
- (2018) Dolores Rodriguez Cumplido et al. Atencion Primaria
- Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization
- (2018) Hongjie Mu et al. DRUG DELIVERY
- Pharmacology study of a chimeric decoy receptor trap fusion protein on retina neovascularization by dual blockage of VEGF and FGF-2
- (2018) Jing Jiang et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Clinical pharmacology of intravitreal anti-VEGF drugs
- (2018) Stefano Fogli et al. EYE
- Biological macromolecules for ophthalmic drug delivery to treat ocular diseases
- (2018) Venkateshwaran Krishnaswami et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Human serum albumin nanoparticles for ocular delivery of bevacizumab
- (2018) Inés Luis de Redín et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- RNA nanoparticle distribution and clearance in the eye after subconjunctival injection with and without thermosensitive hydrogels
- (2018) Zhanquan Shi et al. JOURNAL OF CONTROLLED RELEASE
- Rational design of liposomes for sustained release drug delivery of bevacizumab to treat ocular angiogenesis
- (2018) Devi Kalyan Karumanchi et al. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
- Development of facile drug delivery platform of ranibizumab fabricated PLGA-PEGylated magnetic nanoparticles for age-related macular degeneration therapy
- (2018) Jian Yan et al. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
- Improvement of the transient expression system for production of recombinant proteins in plants
- (2018) Tsuyoshi Yamamoto et al. Scientific Reports
- Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy
- (2018) Xiao-Pei Zhang et al. BIOMEDICINE & PHARMACOTHERAPY
- A review on recent drug delivery systems for posterior segment of eye
- (2018) Kritika Nayak et al. BIOMEDICINE & PHARMACOTHERAPY
- Non-viral ocular gene therapy, pEYS606, for the treatment of non-infectious uveitis: Preclinical evaluation of the medicinal product
- (2018) Elodie Touchard et al. JOURNAL OF CONTROLLED RELEASE
- Anti-angiogenic effect of adiponectin in human primary microvascular and macrovascular endothelial cells
- (2018) Karthikka Palanisamy et al. MICROVASCULAR RESEARCH
- Nonintegrating Gene Therapy Vectors
- (2017) Takis Athanasopoulos et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease
- (2017) Arvind K. Pandey et al. HYPERTENSION
- The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
- (2017) Simon D Harding et al. NUCLEIC ACIDS RESEARCH
- Tyrosine kinase blocking collagen IV–derived peptide suppresses ocular neovascularization and vascular leakage
- (2017) Raquel Lima e Silva et al. Science Translational Medicine
- Nanotechnology-based strategies for treatment of ocular disease
- (2017) Yuhua Weng et al. Acta Pharmaceutica Sinica B
- A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles
- (2017) Flávia Sousa et al. Scientific Reports
- An insight into fusion technology aiding efficient recombinant protein production for functional proteomics
- (2016) Dinesh K. Yadav et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Gene-modified, cell-based therapies—an overview
- (2016) Allison B. Powell et al. CYTOTHERAPY
- Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy
- (2016) Rehan M. Hussain et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Recent perspectives on the delivery of biologics to back of the eye
- (2016) Mary Joseph et al. Expert Opinion on Drug Delivery
- Non-viral gene therapy: Gains and challenges of non-invasive administration methods
- (2016) Marianna Foldvari et al. JOURNAL OF CONTROLLED RELEASE
- Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
- (2016) Jean Bennett et al. LANCET
- PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab
- (2016) Naba Elsaid et al. MOLECULAR PHARMACEUTICS
- MicroRNA-195a-3pinhibits angiogenesis by targetingMmp2in murine mesenchymal stem cells
- (2016) Fan Gao et al. MOLECULAR REPRODUCTION AND DEVELOPMENT
- Pathophysiology and pharmacological targets of VEGF in diabetic macular edema
- (2016) Stefano Fogli et al. PHARMACOLOGICAL RESEARCH
- Targeting VEGF in eye neovascularization: What's new?
- (2016) Marialaura Amadio et al. PHARMACOLOGICAL RESEARCH
- The transgenic animal platform for biopharmaceutical production
- (2016) L. R. Bertolini et al. TRANSGENIC RESEARCH
- Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation
- (2016) Jayamanti Pandit et al. Artificial Cells Nanomedicine and Biotechnology
- Levels of angiogenesis-related vascular endothelial growth factor family in neovascular glaucoma eyes
- (2015) Shida Chen et al. ACTA OPHTHALMOLOGICA
- Polysaccharide-Based Nanocarriers for Ocular Drug Delivery
- (2015) Maria Formica et al. CURRENT PHARMACEUTICAL DESIGN
- Antibody therapies and their challenges in the treatment of age-related macular degeneration
- (2015) Cornelia Volz et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Treatment of ocular disorders by gene therapy
- (2015) M. Ángeles Solinís et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment
- (2015) Reyhaneh Varshochian et al. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
- Nanotechnology-based drug delivery treatments and specific targeting therapy for age-related macular degeneration
- (2015) Tai-Chi Lin et al. Journal of the Chinese Medical Association
- Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminary in vitro studies
- (2015) Luigi Battaglia et al. NANOTECHNOLOGY
- Age-Related Macular Degeneration
- (2015) Sonia Mehta PRIMARY CARE
- Injectable Chemically Crosslinked Hydrogel for the Controlled Release of Bevacizumab in Vitreous: A 6-Month In Vivo Study
- (2015) Yu Yu et al. Translational Vision Science & Technology
- Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
- (2014) Robert L Avery et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis
- (2014) Martin K Schmid et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions
- (2014) C. Biagi et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Intravitreal Aflibercept for Diabetic Macular Edema
- (2014) Jean-François Korobelnik et al. OPHTHALMOLOGY
- Aflibercept—a Decoy VEGF Receptor
- (2014) Kristen K. Ciombor et al. Current Oncology Reports
- Recombinant protein production in bacterial hosts
- (2013) Tim W. Overton DRUG DISCOVERY TODAY
- Accessibility as a Conditioning Factor in Treatment for Exudative Age-related Macular Degeneration
- (2013) Juan P. Real et al. EUROPEAN JOURNAL OF OPHTHALMOLOGY
- The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments
- (2013) Reyhaneh Varshochian et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Hyaluronic acid-based nanocomposite hydrogels for ocular drug delivery applications
- (2013) Leonardus Kresna Widjaja et al. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
- Nanoparticles in Porous Microparticles Prepared by Supercritical Infusion and Pressure Quench Technology for Sustained Delivery of Bevacizumab
- (2013) Sarath K. Yandrapu et al. MOLECULAR PHARMACEUTICS
- In Vitro and In Vivo Efficacy of SYL040012, a Novel siRNA Compound for Treatment of Glaucoma
- (2013) Tamara Martínez et al. MOLECULAR THERAPY
- Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans
- (2012) Tim U. Krohne et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
- (2012) Nicholas Papadopoulos et al. ANGIOGENESIS
- Aflibercept
- (2012) Michael W. Stewart et al. NATURE REVIEWS DRUG DISCOVERY
- Anti-VEGF Treatment Strategies for Wet AMD
- (2012) Jaclyn L. Kovach et al. Journal of Ophthalmology
- Comparing protein VEGF inhibitors: In vitro biological studies
- (2011) Lanlan Yu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Special issue on the production of recombinant proteins
- (2011) Sergio Sanchez et al. BIOTECHNOLOGY ADVANCES
- Biosimilars of Biological Drug Therapies
- (2011) George Dranitsaris et al. DRUGS
- Inflammation in diabetic retinopathy
- (2011) Johnny Tang et al. PROGRESS IN RETINAL AND EYE RESEARCH
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Ron J. Keizer et al. CLINICAL PHARMACOKINETICS
- Renal FcRn Reclaims Albumin but Facilitates Elimination of IgG
- (2009) M. Sarav et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Introduction: Understanding the Role of Angiogenesis and Antiangiogenic Agents in Age-Related Macular Degeneration
- (2009) Susan B. Bressler OPHTHALMOLOGY
- PREPARATION, CHARACTERIZATION, AND IN VIVO EVALUATION OF NANOLIPOSOMES-ENCAPSULATED BEVACIZUMAB (AVASTIN) FOR INTRAVITREAL ADMINISTRATION
- (2009) MAJID ABRISHAMI et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Therapeutic monoclonal antibodies in ophthalmology
- (2008) Eduardo B. Rodrigues et al. PROGRESS IN RETINAL AND EYE RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started